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Abstract: Calcium signaling, in addition to its numerous physiological roles, is also implicated in
several pathological conditions including cancer. An increasing body of evidence suggest critical
roles of calcium signaling in the promotion of different aspects of cancer, including cell proliferation,
therapy resistance and metastatic-related processes. In many cases, this is associated with altered
expression and/or activity of some calcium channels and pumps. Brain cancers have also been
the subject of many of these studies. In addition to diverse roles of calcium signals in normal
brain function, a number of proteins involved in calcium transport are implicated to have specific
roles in some brain cancers including gliomas, medulloblastoma, neuroblastoma and meningioma.
This review discusses research that has been conducted so far to understand diverse roles of
Ca2+-transporting proteins in the progression of brain cancers, as well as any attempts to target these
proteins towards a therapeutic approach for the control of brain cancers. Finally, some knowledge
gaps in the field that may need to be further considered are also discussed.
Keywords: calcium signaling; brain cancers; therapeutic targeting
1. Introduction
Calcium (Ca2+) is a secondary messenger involved in a variety of cellular processes, including
cell growth, apoptosis, differentiation, metabolism, muscle contraction, neuronal plasticity and gene
transcription [1,2]. In addition to its diverse physiological roles, Ca2+ signaling is also implicated
in various pathological conditions, including cancers. Diverse cellular processes critical for
cancer progression are Ca2+ signal-dependent, including proliferation, angiogenesis, invasion and
metastasis [3]. Recently, Ca2+ signaling has also been shown to promote growth and tumorigenesis
of brain cancers. Although, most of these studies so far have been in glioblastomas, an increasing
body of evidence suggest crucial role of Ca2+ signaling in other types of brain cancers too. While the
calcium signal is ubiquitous, the proteins that control Ca2+ transport are not ubiquitously expressed.
Indeed, altered expression and/or activity of specific Ca2+ channels and pumps have been shown
in cancers. These proteins regulate highly specialized and selective processes which contribute to
cancer initiation or progression [1,4]. At the same time, these proteins may not have vital roles in
surrounding normal cells. Thus, altered expression or activity of these proteins in cancers can be
therapeutically exploited to suppress a pathway that is critical for tumorigenesis. Such therapeutic
approaches could be of vital importance in some brain cancer treatment where the current therapeutic
options are inadequate or show debilitating side effects. This review discusses roles and therapeutic
targeting of Ca2+ transporting proteins in brain cancers.
Intracellular Ca2+ signals generated by cells are specific in magnitude, time course and location
and involve various components of calcium signaling toolkit including channels, pumps, exchangers,
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signaling proteins and its dependent effectors. Figure 1 shows an overview of the key components of
Ca2+-transporting proteins, mediating Ca2+ transport in or out of cell, and into or out of intracellular
organelles. Changes in Ca2+ signaling can induce modifications in cell physiology. Therefore, a firm
control on Ca2+ levels within cells is essential [5].
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calcium uniporter (MCU) complex, and mitochondrial Na+/Ca2+ exchanger (NCLX). 
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ionotropic P2X receptors are a class of purine receptors that regulate passage of Ca2+ into the cell in 
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Figure 1. Schematic representation of major calcium channels, pumps, exchangers and sensors
in mammalian cells. Ca2+ influx is mediated by plasma membrane channels including transient
receptor potential (TRP) channels, voltage-gated calcium channels (VGCC), ligand-gated ionotropic
P2X receptors, mechanosensitive Piezo channels, and store-operated Ca2+ entry pathway mediated
by stromal interaction molecule 1 (STIM1) sensor and ORAI1 channels. Distribution of Ca2+
against a chemical gradient across cell compartments is regulated by Ca2+ pumps including the
plasma membrane Ca2+-ATPase (PMCA), Sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA),
and Golgi network secretory pathway Ca2+/Mn2+-ATPase (SPCA). The endoplasmic reticulum (ER)
Ca2+ channels include ryanodine receptor (RYR) and inositol 1,4,5-trisphosphate (IP3) receptor (IP3R);
the latter is activated by IP3 ligand produced by the plasma membrane G protein-coupled receptor
(GPCR) via Gaq and phospholipase C-β (PLCβ) proteins. Two-pore channels (TPC) regul te Ca2+
release from the endolysosomal system. Mitochondrial Ca2+ levels are controlled by mitochondrial
calcium uniporter (MCU) complex, and mitochondrial Na+/Ca2+ exchanger (NCLX).
Normal cell functioning requires maintenance of varied distribution of Ca2+ against a chemical
gradient across cell compartments which is carried out and regulated by energy driven Ca2+ pumps.
These pumps change the affinity and availability of Ca2+ binding sites within cell compartments with
variation in Ca2+ concentrations [6]. Sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA),
plasma membrane Ca2+-ATPase (PMCA) and Golgi network secretory pathway Ca2+/Mn2+-ATPase
(SPCA) re the main pumps found i m m als. An upward or downregulated expression of Ca2+
pumps is observed in various ca ce s and is believed to promote diff rentiation and apoptosis
resistance in tumor c lls [6]. Ca2+ signals are mediated by inositol 1,4,5-trisphosphate (IP3) receptor
and ryanodine receptors (RyRs) in sarco and endoplasmic reticulum. Voltage-gated Ca2+ channels
(VGCC), transient receptor potential (TRP) ion channels, store-operated Ca2+ entry (SOCE) channels,
and ligand-gated Ca2+ channels are involved in movement of Ca2+ ion across plasma membrane. For
instance, TRP channels, also known as cellular sensors [7], consists of a number of cation channels that
mediate cellular functions such as cell growth, apoptosis and motility [8]. Ligand-gated ionotropic
P2X receptors are a class of purine receptors that regulate passage of Ca2+ into the cell in response
to extracellular ATP [9]. Piezo channels are plasma membrane mechanosensitive channels that are
stimulated by mechanical forces (Figure 1). A detailed description of components and complexity of
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Ca2+ signaling has been reviewed extensively elsewhere [2,10,11]. Intracellular Ca2+ can be derived
from both internal (such as endoplasmic or sarcoplasmic reticulum) and external sources (such as
via plasma membrane ion channels). Ca2+ produces signals in the form of waves and spikes. Spikes
activate localized cellular processes, while Ca2+ waves occur when individual channels communicate
with each other to produce global signals leading to activation of both intercellular (such as functioning
of glial cells) and intracellular (such as gene transcription and cell proliferation) functions [12]. Ca2+
signals for longer periods are relayed via repetitive Ca2+ pulses known as oscillations. Both Ca2+
spikes and waves can produce oscillating signals triggering different processes depending upon their
signal duration [12].
2. Calcium Signaling in Cancer
In recent years, studies elucidating the molecular mechanism involved in cancer have led to an
enhanced understanding of various factors that play a role in disease progression and complexity [13].
In an attempt to simplify the complex biology underlying the disease, Hanahan and Weinberg in
their review, “The hallmarks of cancer: the next generation”, introduced ten key characteristics of
the neoplastic cells. These are maintenance of long term growth signaling, resistance to cell death,
angiogenesis induction, metastasis instigation, growth suppressor evasion, uncontrolled proliferation
potential, unstable genome and mutation, energy metabolism reprogramming, evasion of immune
system and presence of tumor promoting inflammation [14]. Cancer pathology reveals genetic changes
in the growth signaling that impair tightly regulated normal cell homeostasis leading to transformation
of normal cells into malignant type with uncontrolled proliferative potential [15]. A growing body of
evidence suggests that ion channels play a pivotal role in tumor biology and are involved in regulation
of tumor cell characteristics such as uncontrolled growth, sustained angiogenesis, metastasis and
resistance to apoptosis [16]. In some cases, this regulation occurs via the transmission of signals
from the tumor microenvironment. For instance, the involvement of Ca2+ channels in regulation of
epithelial to mesenchymal transition (EMT) [17], a process critical for cancer metastasis [18,19] and
also contributes to drug resistance [20].
In tumor cells, altered Ca2+ movement often involves aberrant expressions, cellular localization
and activity of Ca2+-transporting proteins contributing towards tumor specific characteristics such
as unlimited growth, metastasis and resistance to apoptosis [3,4]. Since Ca2+ signals are vital for
normal cell function, alteration in these signals may lead to modified calcium codes that can trigger
tumorigenic behavior. Ca2+ pulses serve as “calcium codes” differing in magnitude, time and frequency.
Prolonged Ca2+ pulses are involved in cell division process, angiogenesis, differentiation and genomic
instability in cancer cells [21].
Brain Cancers
Brain cancers are neoplasms that originate within the brain and spinal cord mainly from neurons
or glial cells (astrocytes, oligodendrocytes and ependymal cells), and occasionally from pituitary gland,
meninges, lymphatic tissue and cranial nerves [22]. These tumors exhibit with varying degrees of
malignancy and are associated with high mortality and morbidity in both children and adults [22,23].
Medulloblastomas (MBs), ependymomas and high-grade gliomas are the most prevalent tumors
affecting children and adults [23]. Medulloblastoma, arising from immature neuronal precursors
of cerebellum, affects about 25% of pediatric brain cancer patients [24]. For treatment, patients are
divided into standard and high-risk groups. High-risk patients have residual tumor mass of >1.5 cm2
showing metastasis, whereas low risk patients have residual tumor with the size of < 1.5 cm2 without
metastasis. Current therapies for medulloblastomas include surgery, radiotherapy and chemotherapy.
The use of chemotherapeutic agents as an adjuvant has led to improved results and radiation dose
reduction [25].
Ependymomas, accounting for approximately 10% of pediatric brain tumors, originate from
ependymal cells that form the lining of the spinal cord and ventricles of the brain [25]. Recent studies
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indicate that ependymomas have varied genetic aberrations and transcriptional profiles depending
upon their location within the central nervous system. Surgery and irradiation remain the mainstay of
treatment, as chemotherapy shows limited efficacy in most patients [25,26].
In adults, the most common type of brain tumor is high-grade gliomas. It includes glioblastoma
and anaplastic astrocytoma [27]. Current treatment options include maximal surgical resectioning,
followed by radiation and adjuvant temozolomide chemotherapy. For anaplastic gliomas, the standard
treatment is surgery and radiotherapy, as the efficacy of chemotherapy remains uncertain [27].
Despite improving the survival rate of patients, current therapies pose serious complications that
impact quality of life in patients. Traumatic injuries such as damage to blood vessels and ischemia
are common problems associated with surgical resectioning, while radiation and chemotherapy
cause neurocognitive deficits, cerebral necrosis, peripheral neuropathy, myelopathy and secondary
neoplasms [28]. Current neoplastic treatments not only cause neurological complications, but also
act as precursor to problems such as tumor relapse [29]. Lack of specific targeting of tumor cells by
standard care therapies results in damage to normal cells leading to systemic toxicity. Furthermore,
their inability to kill cancer stem cells (CSCs), that possess self-renewal properties, leads to appearance
of secondary tumors [30]. CSCs are rare population of tumor cells that have the ability to multiply
and differentiate via both symmetrical and asymmetrical cell division. These cells play a key role
in initiation, growth, maintenance, metastasis and survival of cancers. It is, therefore, essential to
develop treatments that specifically target and eliminate CSCs with minimal damage to normal cells
for more effective clinical outcomes [31]. Recent studies have indicated the involvement of calcium
channels in controlling a number of functions important in CSCs such as cell volume, progression,
metastasis and angiogenesis and therefore, deregulated calcium signaling could serve as a target for
cancer therapy [32].
3. Calcium Signaling in the Brain
Ca2+ channels play crucial role in nervous system development. Short-term rise in Ca2+ levels,
known as calcium transients, are believed to play an important role in mediating various neuronal
development stages such as growth, migration, differentiation, survival and formation of neuronal
network by maintaining different influx patterns [33].
In brain, key functions of neurons are regulated by flow of Ca2+ between the intracellular
compartments and across plasma membrane in brain. The movement of Ca2+ is triggered in response
to stimulus such as membrane depolarization, intracellular Ca2+ store depletion, mechanical stretch,
extracellular agonists and intracellular messengers [34].
The influx of Ca2+ leads to induction of a number of Ca2+ dependent processes such as
neurotransmitter release, neuronal excitability, synaptic plasticity, memory storage and gene
expression [35–37]. This diversity in neural functions mediated by Ca2+ signal is a result of distinctive
signals that differ in their scale, temporal and spatial properties [34]. Specific changes in the Ca2+
concentration results in distinct function modification in the same neuron types depending upon the
short, medium and long duration and distance travelled by the signal [34].
Ca2+ regulated functions involve a set of ion channels, exchangers and pumps present in plasma
membrane, mitochondria, endoplasmic reticulum, golgi apparatus and nucleus, collectively known as
Ca2+ toolkit. These Ca2+-transporting proteins together with G protein-coupled receptors, Ca2+ binding
proteins, and related transcriptional networks mediate functions important for brain physiology [38].
4. Ca2+-Transporting Proteins in the Progression of Brain Cancers
The following section summarizes the specific roles of Ca2+-transporting proteins in brain cancers.
Most of these studies are conducted in glioma cells, with some research focusing on medulloblastoma,
neuroblastoma and meningioma cells. Table 1 summarizes studies showcasing specific roles of
Ca2+-transporting proteins in the progression of brain cancers. It should be noted that in this review,
we only discuss studies that show direct association of Ca2+ transporters and not the ones based on
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other ion transporters that are Ca2+ dependent. This is, exemplified, by the role of calcium-activated
potassium channel KCa3.1 in glioma cell migration, invasion and temozolomide resistance [39].
4.1. Calcium Signaling in Glioma Cells
4.1.1. Store-Operated Ca2+ Entry (SOCE) in Glioma Cells
SOCE is a process of Ca2+ influx to refill the endoplasmic reticulum’s (ER) Ca2+ after depletion.
This process is initiated when the reduced levels of ER Ca2+ are sensed by STIM1 leading to its
oligomerization and interaction with ORAI1 Ca2+ channel on the plasma membrane consequently
resulting in the opening of the channel and influx of Ca2+ [40]. In primary human glioblastoma cells,
higher levels of SOCE and ORAI1 expression have been observed in comparison to non-malignant
human primary astrocytes [41]. While small interfering RNA (siRNA)-mediated silencing of ORAI1
(but not STIM1) marginally reduces cell proliferation, silencing of both ORAI1 and STIM1 dramatically
reduces invasion of glioblastoma cells [41]. In another study, pharmacological inhibition of SOCE
and ORAI1 silencing, led to decrease in cell proliferation and induction of apoptosis in glioblastoma
cells [42].
4.1.2. Voltage-Gated Calcium Channels (VGCCs) in Glioma Cells
In neurons, Ca2+ influx is regulated by VGCCs. Opening of these channels results in high
intracellular Ca2+ levels that activate processes such as neurotransmitter release, neuron growth
and gene expression [43]. VGCCs are divided into three main categories: high voltage activated
channels (including P/Q-type, N-type and L-type), intermediate voltage activated R-type channels,
and low voltage activated T-type channels (CaV3 channels) [44]. T-type Ca2+ channels control
processes such as cell proliferation and differentiation by regulating Ca2+ levels at low voltage
through creation of resting inward calcium current. Aberrant expression of T-type Ca2+ channels is
observed in diverse tumor types [45]. In human glioblastoma cells, mibefradil, a T-type Ca2+ channel
blocker with a weak L-type channel inhibiting activity [46], and siRNA-mediated downregulation of
CACNA1G (CaV.3.1) and CACNA1H (CaV3.2) reduces cell proliferation, induces apoptotic cell death,
and sensitizes cells to ionizing radiation via AKT/mTORC2 axis [47]. In another study, treatment
with mibefradil was shown to enhance the efficacy of subsequently administered temozolomide
in human glioblastoma xenograft lines grown in immunodeficient mice [48]. More recently, small
hairpin RNA (shRNA)-mediated silencing of CaV3.2 or mibefradil treatment was shown to inhibit
the proliferation, survival and stemness features of glioblastoma stem-like cells (GSC) as well as
sensitize them to temozolomide chemotherapy [49]. This regulation was shown to be mediated
by inhibition of pro-survival AKT/mTOR pathway, promotion of proapoptotic survivin and BAX
pathways, and modulation of the expression of number of oncogenes and tumor suppressor genes [49].
Mibefradil, taken orally, suppressed growth of GSC-derived xenografts, increased survival and
enhanced temozolomide sensitivity [49].
4.1.3. TRP Channels in Glioma Cells
TRP channels are expressed in a number of tissues where they control diverse cellular functions such
as cell growth, proliferation, differentiation, migration and apoptosis [50]. TRP channels are activated by
both chemical and physical stimuli as well as through changes in cell microenvironment [50]. Number of
studies have shown the important roles of TRP channels in glioma progression. In D54MG glioblastoma
cells, treatment of cells with SKF96365 (a non-selective TRP-canonical (TRPC) channel blocker) led to
inhibition of cell proliferation and cytokinesis [51]. In another study, shRNA mediated suppression of
TRPC1 or treatment with SKF96365 in D54MG glioma cells, resulted in inhibition of cell proliferation
and incomplete cell division [52]. This study also showed that shRNA suppression of TRPC1 in a flank
tumor model, reduced tumor size [52]. Further studies demonstrated that motility of D54MG cells
stimulated by epidermal growth factor (EGF), is regulated by TRPC1 channels, in a manner that is
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dependent on lipid raft proteins [53]. Another TRPC member, TRPC6, was shown to have a crucial role
in cell growth, clonogenic ability and G2/M phase cell cycle transition, and its inhibition promoted
antiproliferative effects of ionizing radiation [54].
Calcium signaling regulates hypoxia-associated pathways, and several Ca2+-transporting proteins
are shown to interplay with hypoxia-inducible factor-1 (HIF-1), which is master regulator of hypoxia
transcriptional responses [55,56]. In glioma cells, TRPC6 is activated by hypoxia, where it contributes
to hypoxic elevation of intracellular Ca2+. Inhibition of TRPC6, by shRNA or expression of its
dominant-negative mutant (DNC6), abolished hypoxia-induced HIF-1α protein accumulation in U251
human glioblastoma cells via promotion of HIF-1α hydroxylation [57]. Hypoxic activation of TRPC6
was also shown to contribute to cell metabolism via regulation of glucose transporter 1 (GLUT1)
expression and glucose uptake [57]. In another study, hypoxic upregulation of TRPC6 expression (via
Notch signaling), resulted in activation of nuclear factor of activated T-cells (NFAT), proliferation,
invasion and angiogenesis of glioblastoma cells [58].
A number of TRP-melastatin (TRPM) channels have been implicated in glioblastoma progression:
reactive oxygen species (ROS)-activated TRPM2 channel induces cell death in A172 human
glioblastoma cells [59]; TRPM7 channel promotes proliferation and migration of A172 cells possibly
through activation of JAK2/STAT3 and Notch signaling pathways [60]; and TRPM8 channel, via
activation of the large-conductance Ca2+-activated K+ membrane ion channels (BK channels), regulates
migration of DBTRG glioblastoma cells [61,62].
TRP-vanilloid (TRPV) channels also have important functions in gliomas. Activation of TRPV1 by
capsaicin, leads to Ca2+ influx and induction of apoptosis in U373 human glioblastoma astrocytoma cells
via p38 mitogen-activated protein kinases (MAPK) activation [63]. Interestingly, neural precursor cells,
in an antitumorigenic response, migrate to high-grade astrocytoma cells and activate highly-expressed
TRPV1 channels on these cells by releasing endovanilloids. This activation results in cancer cell death
via activating transcription factor-3 (ATF3)-dependent ER stress pathway [64]. Cannabidiol-induced
TRPV2 channel potentiates chemosensitivity of carmustine, temozolomide and doxorubicin in
U87MG and MZC cells [65]. TRPV2 was shown in another study, to negatively regulate glioma
cell proliferation and survival, and resistance to extracellular signal-regulated kinase (ERK) dependent
Fas-induced apoptotic cell death [66]. Another study in in vitro and in vivo models showed that TRPV2
enhances glioblastoma stem-like cells (GSCs) differentiation toward a more mature glial phenotype,
and suppresses their proliferation [67].
4.1.4. IP3 Receptors in Glioma Cells
IP3 receptors (IP3R) convert external stimulus to intracellular Ca2+ signals of diverse spatial
and temporal patterns such as waves and oscillations [68]. In glioblastoma cells, pharmacological
inhibition of IP3R3 by caffeine, reduces cell invasion and migration, and increases survival of subject
animals [69].
4.1.5. P2X Receptors in Glioma Cells
Members of the P2X receptors have been shown to play roles in different cancer types [70].
In gliomas, several studies have implicated the role of P2X7 receptors. In rat C6 glioma cells,
activation of P2X7 receptors promoted cell migration and expression of pro-inflammatory factors [71].
In another study in C6 cells, P2X7 receptor suppression via use of antagonist or shRNA, promoted
epidermal growth factor receptor (EGFR) signaling and growth of cells in in vitro, and tumor growth
and angiogenesis in rat-transplanted in vivo models [72]. Intriguingly, P2X7 receptor activation
in radiosensitive M059J cells resulted in enhanced cell death [73]. Indeed, P2X7 receptor was later
proposed as a predictor gene for glioma patient radiosensitivity and survival probability [74]. In 1321N1
astrocytoma cells, P2X7 receptor was shown to activate ERK1/2 phosphorylation via activation of
proline-rich tyrosine kinase 2 (Pyk2), c-Src, phosphatidylinositol 3′-kinase (PI3K), and protein kinase C
(PKC) [75].
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4.2. Calcium Signaling in Medulloblastoma Cells
In medulloblastoma cells, proton-sensing ovarian cancer G protein-coupled receptor 1 (OGR1)
promotes the expression of TRPC4 channels in transformed granule cells (DAOY cells). TRPC4
channels in these cells (but not in normal cerebellar granule precursor cells), enhances cell motility in
wound healing and transwell migration assays [76].
4.3. Calcium Signaling in Neuroblastoma Cells
In mouse N1E-115 neuroblastoma cells, using plasmid overexpression, siRNA-mediated silencing
or mibefradil treatment, it was shown that CaV3.1 and CaV3.2 promote cell proliferation [77]. CaV3.2
also stimulates differentiation of NG108-15 cells via an autocrine mechanism of facilitating extracellular
secretion of differentiation-promoting factors [78].
Full-length and short isoforms of the TRPM2 channels (TRPM2-L and TRPM2-S respectively)
are shown to be upregulated in neuroblastoma tissues compared to adrenal glands [79]. SH-SY5Y
neuroblastoma cells stably expressing TRPM2-L showed enhanced protection against cell death
induced by oxidative stress via increased forkhead box transcription factor 3a (FOXO3a) and
superoxide dismutase 2 (SOD2) levels, while cells expressing TRPM2-S showed enhanced levels
of ROS and reduced cell viability [79,80]. TRPM2-S expressing SH-SY5Y xenografts showed reduced
HIF-1/2α levels and their target proteins, as well as reduced tumor growth [80]. Pharmacological
inhibition of TRPM2-L or expression of TRPM2-S enhanced sensitivity of cells to doxorubicin [80].
P2X7 receptors, in addition to glioma cells that was discussed above, plays role in neuroblastoma
cells too. In neuroblastoma cells lacking trophic support (serum-deprived), P2X7 receptor expression
is enhanced via EGFR and PI3K/AKT pathway, where it facilitates cell proliferation [81].
Retinoic acid-mediated differentiation of neuroblastic (N-type) SH-SY5Y cells was shown to be
associated with downregulation of SOCE and expression of STIM1 and ORAI1 proteins [82]. Similarly,
in another study, an increase in Ca2+ efflux and expression of PMCA2, PMCA3 and PMCA4 was
observed in differentiated IMR-32 neuroblastoma cells compared to undifferentiated cells [83]. In both
these studies, however, it was not discussed if SOCE or PMCA pumps are involved in the induction of
differentiation or these altered activity/expression are consequences of differentiation.
Treatment of neuroblastoma cells with chemotherapeutic agents, cisplatin and topotecan,
increased intracellular Ca2+ levels over time. Furthermore, expression of S100A6, IP3R1, IP3R3, RYR1,
RYR3 were altered upon treatment with cisplatin and topotecan, and pharmacological modulators
of Ca2+-transporting proteins in combination with these two agents enhanced cytotoxicity [84].
Further studies are needed to determine the specific roles of these Ca2+-transporting proteins in
neuroblastoma progression.
4.4. Calcium Signaling in Meningioma Cells
VGCCs are shown to promote meningioma cells. The addition of diltiazem and verapamil
(mainly L-type calcium channel blockers) to meningioma chemotherapy drug hydroxyurea (HU),
and the antiprogesterone, mifepristone (RU486), enhanced cell growth inhibition through induction
of apoptosis and G1 cell-cycle arrest in vitro. This approach also decreased tumor size in meningioma
subcutaneous mouse flank tumors through suppression of proliferation and microvascular density [85,86].
Figure 2 compiles different processes of brain cancer progression assessed in these studies into
distinct categories of cellular processes and places each Ca2+ channel/regulator into its relevant process
where it has shown involvement. These processes include proliferation, migration, invasion, therapy
resistance/therapy sensitivity, differentiation, angiogenesis, inflammation and cell death. Many of
these processes are involved in cancer hallmarks.
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Table 1. Ca2+-transporting proteins with demonstrated specific roles in brain cancers.
Cancer Channel/Regulator Model TargetingApproach Role of Channel/Regulator References
Glioma
STIM1, ORAI1 Primary GB cells siRNA Regulates proliferation (onlyORAI1) and invasion [41]
ORAI1 U251, C6 cells siRNA, antagonist Regulates cell proliferation andapoptosis [42]
Cav3.1, Cav3.2 U251, U87 andT98G cells siRNA, antagonist
Regulate apoptosis and
proliferation, and sensitize cells to
ionizing radiation
[47]
Cav3.2
GB primary stem
cells, Xenografted
mice
siRNA, antagonist Promotes proliferation andstemness. Sensitizes cells to TMZ * [49]
TRPC1 D54MG cells, flanktumor shRNA, antagonist
Promotes cell proliferation and
cytokinesis, as well as tumor size [52]
D54MG cells shRNA, antagonist Promotes cell motility [53]
TRPC6 U251, U87, C6 cells,Xenografts
shRNA, DNC6 *
antagonist
Promotes cell growth, clonogenicity,
and G2/M transition [54]
U251 cells shRNA, DNC6 *antagonist
Induces HIF-1α accumulation and
glucose uptake [57]
U373, HMEC-1
cells siRNA
Promotes NFAT activation, cell
proliferation and angiogenesis [58]
TRPM2 A172 cells Overexpression Induces cell death [59]
TRPM7 A172 cells siRNA Promotes proliferation andmigration [60]
TRPM8 DBTRG cells Agonist, antagonist Promotes cell migration [61,62]
TRPV1 U373 cells Agonist Induces apoptosis [63]
TRPV2 U87MG, MZC cells Agonist Increases chemosensitivity [65]
U87MG, MZC cells siRNA,overexpression
Negatively regulates proliferation
and resistance to cell death [66]
GB primary stem
cells
Antagonist, siRNA,
overexpression in
xenograft
Promotes differentiation and
inhibits proliferation [67]
IP3R3
U178, U87, T98G
cells, Organotypic,
Xenograft
Antagonist Regulates invasion and migration [69]
P2X7R C6 cells Agonist Promotes migration andinflammation [71]
C6 cells, Xenograft Antagonist,shRNA
Negatively regulates cell
proliferation, tumor growth and
angiogenesis
[72]
M059J, GL261 cells Agonist,antagonist, siRNA Promotes cell radiosensitivity [73,74]
1321N1 cells Agonist Promotes ERK1/2 activation [75]
MB TRPC4 DAOY, ONS76cells, Organotypic
Agonist,
antagonist,
overexpression
Promotes cell motility [76]
Neuroblastoma
Cav3.1, Cav3.2 N1E-115 cells siRNA, antagonistoverexpression Promotes cell proliferation [77]
Cav3.2 NG108-15 cells siRNA Promotes cell differentiation [78]
TRPM2 SH-SY5Y cells,Xenograft
Overexpression,
antagonist Regulates cell death/viability [79,80]
P2X7R N2a cells Antagonist Promotes cell proliferation [81]
Meningioma L-type channels IOMM-Lee cells,xenograft Antagonist
Promotes apoptosis and cell-cycle
arrest [85,86]
* DNC6, Expression of the dominant-negative mutant TRPC6; GB, glioblastoma; TMZ, temozolomide;
MB, medulloblastoma.
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5. Targeting Calcium Signaling Pathways as a Therapeutic Approach for Brain Cancers
In the previous section, we discussed studies that have shown important roles of Ca2+-transporting
proteins in the promotion of different aspects of brain cancer progression. In this section, we discuss
studies that are more translational and are conducted in in vivo preclinical models or in clinical trials.
Table 2 summarizes clinical trial studies that are completed or currently underway in brain
cancers using modulators of Ca2+-transporting proteins and outlines the outcomes of these studies.
Perhaps one of the most important studies, is recent completion of phase II clinical trial of
Mipsagargin (also known as G-202) for recurrent or progressive glioblastoma (NCT02067156), as well
as for prostate cancer [87]. Mipsagargin which is a SERCA pump inhibitor, is an analogue of
thapsigargin. Mipsagargin is a non-toxic prodrug that is activated through binding to and cleavage by
prostate-specific membrane antigen (PSMA) that is rich in many cancers [87]. Mibefradil, has been
also at the center of attention for clinical trials. Indeed, two clinical trials of phase I were recently
completed for assessment of mibefradil in combination with temozolomide (NCT01480050, [88])
or hypofractionated radiation (NCT02202993, [89]) for recurrent glioblastoma. These treatments
were well-tolerated in patients and showed some promising responses in selective of patients
suggesting that these treatments warrant further investigation [88,89]. A phase I clinical trial was also
recently completed for assessment of carboxyamidotriazole orotate (CTO), an inhibitor of non-voltage
dependent calcium channels (blocking both the Ca2+ influx and release from intracellular stores), for
recurrent and newly diagnosed glioblastoma and other anaplastic gliomas (NCT01107522, [90,91]).
This study showed safe co-administration of CTO with temoxolomide or chemoradiation, favorable
brain penetration and promising signals of activity in patients [90,91]. A Phase II study focusing on
combination of verapamil and hydroxyurea (HU) for refractory meningiomas showed no effect of HU
or verapamil on tumor recurrence and progression-free survival (PFS) [92].
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Table 2. Modulators of Ca2+-regulating proteins in clinical trials for treatment of brain cancers.
Intervention Channel/PumpTargeted Disease
Clinical
Phase
Study End
Year Results NCT
# References
Verapamil
+Hydroxyurea (HU)
L-type
channels
Refractory
Meningiomas II 2015
No effect of HU or
verapamil on tumor
recurrence and PFS
00706810 [92]
Mipsagargin SERCA pump
Recurrent or
progressive
GB
II 2017 Favorable tolerability andpharmacokinetic profile 02067156 [87]
Mibefradil
+Temozolomide
T-type
channels
Recurrent
Glioma I 2017
Well tolerated and
promising responses
in patients
01480050 [88]
Mibefradil
+Hypofractionated
radiation
T-type
channels Recurrent GB I 2017
Safe co-administration,
effective brain penetration,
and promising local control
signals in some patients
02202993 [89]
CTO
+Temozolomide or
chemoradiation
Non-voltage
channels
GB and other
anaplastic
gliomas
I Still active
Safe co-administration,
favorable brain penetration,
and promising signals
of activity
01107522 [90,91]
GB, glioblastoma; PFS, progression-free survival; CTO, Carboxyamidotriazole orotate.
Apart from these clinical studies, there have also been some exciting pre-clinical studies in
in vivo models with translational potential. In a recent study, pharmacological targeting of T-type
Ca2+ channels with niguldipine and mibefradil, induced selective cell death of glioma-initiating
cells and enhanced host survival in an orthotopic mouse model of human glioma [93]. In another
study, trifluoperazine (TFP), a well-known antipsychotic, inhibited proliferation (via induction of cell
death), migration and invasion of glioblastoma cells in vitro, and tumor growth in in vivo xenograft
mouse model. This effect was shown to be via direct binding of TFP to the Ca2+-binding protein,
calmodulin subtype 2 (CaM2), leading to dissociation of CaM2 from IP3R and subsequent extensive
and irreversible Ca2+ release from endoplasmic reticulum by IP3R1 and IP3R2. Interestingly, this study
also showed that TFP has less toxic effects on neural stem cells compared to glioblastoma cells [94].
Bradykinin, a neuropeptide of the vasculature, was shown to induce Ca2+ release from internal stores,
which ultimately led to increase of glioma invasion. This was shown to be mediated by inducing
amoeboid migration via contraction of the cytoskeleton and activation of Ca2+-dependent K+ and Cl−
channels [95]. As also discussed in previous section, another recent study demonstrated novel roles
of CaV3.2 in glioblastoma stem-like cells and further supported the use of mibefradil in combination
with temozolomide for glioblastoma therapy [49]. Furthermore, in vitro studies in glioblastoma
cells demonstrated enhanced radiosensitivity with TRPC6 inhibition [54], while activation of TRPV2
channel increased chemosensitivity of cells [65]. P2X7 receptor activation also led to an increase in
radiosensitivity of glioblastoma cells both in vitro [73] and in vivo [74].
Altogether, these studies showcase promising approaches of therapeutic targeting Ca2+ signaling
pathways for the control of brain cancers. It is interesting to note that the therapeutic targeting of
plasma membrane Ca2+ channels in brain cancers has been focused on the use of blockers of these
channels and no study has used channel activators to induce cytosolic Ca2+ overload and subsequent
cell death, as was recently shown in breast cancer cells through activation of TRPV4 channel [96].
6. Conclusions and Perspectives
As discussed throughout the paper, a number of studies suggest involvement of Ca2+-transporting
proteins in different aspects of brain cancer progression. Interestingly, all the proteins that were
identified in these studies were Ca2+ channels of different classes (except from STIM1 that is an ER Ca2+
sensor). These Ca2+ channels included T-type voltage-gated channels, number of TRP channels, ORAI1,
IP3R3 and P2X7R. As shown in Figure 2 many of the cellular processes that are regulated by these
proteins are involved in cancer hallmarks. It should be noted that these studies identify roles of Ca2+
signaling and specific transporting proteins in the progression of cancer, however it would be interesting
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and critical to also assess if calcium signaling and its regulating proteins are involved in the initiation
of brain cancers. Furthermore, many of these studies are conducted in in vitro models of cancer cells
(in most cases continuous cell lines). While these in vitro continuous cell line models provide very
important information, these studies need to be also conducted in primary brain cancer cells and
in vivo models to have a better understanding of potential translational impact. It is also imperative
that in addition to cancer cells, the effect of targeting identified proteins be assessed in normal brain
cells, highly sensitive cells that when damaged can result in debilitating permanent side-effects.
As was shown, majority of the research conducted so far in the field of calcium signaling in
brain cancer has been undertaken in glioma cells with most of it in the past few years, underlining
that there remain many unanswered research questions in this emerging field. In particular, role of
Ca2+-transporting proteins in transmitting the signals from the brain tumor microenvironment to
cancer cells, is an area of research that requires further investigation.
Ion channels are reported to represent 18% of all FDA-approved small-molecule drug targets [97].
Given the extensively long and expensive process of drug development, assessment of these existing
drugs in brain cancers, alone or in conjunction with current therapies, may provide the opportunity of
rapid drug re-purposing for brain cancer therapy. In light of the extensive roles of calcium signaling
in normal function of cells, the challenge lies in targeting calcium signaling proteins without causing
major side effects. Current advancements in several fields can assist in achievement of this goal,
including advancement in development of more selective and less toxic compounds, integrative
genomics and transcriptomics studies providing gene maps of brain cancers, and novel drug delivery
and activation approaches. These will significantly contribute towards safe and effective therapeutic
targeting of Ca2+-regulating proteins in coming years.
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